227 results on '"Mayer, Erica L."'
Search Results
2. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502
3. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
4. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial
5. Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial
6. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
7. ASO Visual Abstract: Racial and Ethnic Disparities in Outcomes after Breast-Conserving Therapy and Endocrine Therapy for DCIS—A Post Hoc Analysis of the NSABP B-35 Randomized, Clinical Trial
8. ASO Visual Abstract: Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial
9. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
10. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
11. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
12. Single duplex DNA sequencing with CODEC detects mutations with high sensitivity
13. Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
14. ‘ADVANCE’ (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer
15. Emerging Targeted Therapies for Early Breast Cancer
16. Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis
17. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
18. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
19. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
20. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative...
21. Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors.
22. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
23. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
24. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
25. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
26. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
27. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
28. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
29. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
30. Randomized trial of a clinic-based weight loss intervention in cancer survivors
31. Treatment of Breast Cancer During Pregnancy
32. Adjuvant endocrine therapy for postmenopausal women: Type and duration
33. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
34. Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
35. Prognosis of pregnancy-associated breast cancer
36. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
37. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
38. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
39. Targeting Breast Cancer with CDK Inhibitors
40. Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
41. Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
42. Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer
43. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer
44. Prospective clinical experience with research biopsies in breast cancer patients
45. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
46. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
47. What's the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
48. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
49. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics
50. Anti-Angiogenic Strategies in Breast Cancer: An Update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.